Sionna Therapeutics Reports Third Quarter 2026 Financial Results
Globe Newswire•10/11/2026•07:00 ET
0
Key Highlights
- ➤Sionna plans AscenSION CF Phase 2 trial initiation in Q1 2027
- ➤Cash, equivalents and marketable securities totaled $249.8 million, funding operations into H2 2029
- ➤Sionna discontinued SION-719 add-on development after PreciSION CF missed its key endpoint
- ➤Workforce reduction of approximately 46% supports focus on SION-451 + SION-2222
- ➤Q3 net loss widened to $32.4 million from $20.3 million year over year
Expert Statements
Mike Cloonan, President and Chief Executive Officer of Sionna Therapeutics
“During the third quarter, we established a focused path forward for Sionna centered on SION-451 + SION-2222, our proprietary, NBD1-anchored dual combination”
Mike Cloonan, President and Chief Executive Officer of Sionna Therapeutics
“We believe the findings from the PreciSION CF post hoc analyses, together with the dual combination’s favorable Phase 1 results, support advancing the dual combination into the next phase of development.”
Mike Cloonan, President and Chief Executive Officer of Sionna Therapeutics
“With our resources focused on developing this program and cash runway expected into the second half of 2029, we are well-positioned to execute our strategy to deliver new treatment options for people with CF.”
Advancing SION-451 + SION-2222 dual combination to AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in the first quarter of 2027
Clinical and nonclinical data presented at 2026 NACFC support advancement of SION-451 + SION-2222 and the potential of NBD1 stabilizer combinations to benefit a broad population of people with CF
Get started
Create a free account to read the full story.